Clinical Trials
34 trialsLenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
The First Affiliated Hospital of Xiamen University
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
National Cancer Institute (NCI)
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
National Institutes of Health Clinical Center (CC)
IIT Sutent
Medstar Health Research Institute
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
National Cancer Institute (NCI)
Thalidomide in Treating Patients With Thyroid Cancer
University of Kentucky
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
University of Washington
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Sanofi
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
National Cancer Institute (NCI)
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
Amgen
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
Exelixis
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NGR-TNF in Treating Patients With Advanced Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
European Organisation for Research and Treatment of Cancer - EORTC
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Case Comprehensive Cancer Center